Skip to content

Discontinued — last reported Q1 '26

D&A at other companies

Globus Medical logo
Globus MedicalGMED
$29.53M-55.3%
Medtronic logo
MedtronicMDT
$716M-14.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%
CONMED logo
CONMEDCNMD
$8.7M0.0%
Artivion logo
ArtivionAORT
$6.34M+16.4%
Henry Schein logo
Henry ScheinHSIC
$81M+11.0%

Segments

By segment

See full
Specialty Surgery$0
Tissue Reconstruction$0

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's D&A?
Integra LifeSciences (IART) reported D&A of $3.78M in Q1 2026.
How has Integra LifeSciences's D&A changed year-over-year?
Integra LifeSciences's D&A increased by 1.9% year-over-year, from $3.7M to $3.78M.
What is the long-term trend for Integra LifeSciences's D&A?
Over 4 years (2021 to 2025), Integra LifeSciences's D&A has grown at a -3.0% compound annual growth rate (CAGR), from $16.91M to $14.95M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.